Intensive management from diagnosis improves HbA1c at 12 months post-diagnosis: results from a prospective cohort study in children with newly diagnosed type 1 diabetes.

Publisher: Pasifika Medical Association Group Country of Publication: New Zealand NLM ID: 0401067 Publication Model: Electronic Cited Medium: Internet ISSN: 1175-8716 (Electronic) Linking ISSN: 00288446 NLM ISO Abbreviation: N Z Med J Subsets: MEDLINE

Publication: 2022- : Auckland : Pasifika Medical Association Group
Original Publication: Wellington : New Zealand Medical Association

Diabetes Mellitus, Type 1*/diagnosis ; Diabetes Mellitus, Type 1*/drug therapy; Child ; Humans ; Adolescent ; Glycated Hemoglobin ; Blood Glucose ; Blood Glucose Self-Monitoring/methods ; Prospective Studies ; New Zealand ; Insulin/therapeutic use ; Hypoglycemic Agents/therapeutic use

Aims: To examine the impact of intensive management of type 1 diabetes (T1D) from diagnosis on HbA1c 12 months from diagnosis.
Methods: HbA1c measured 12 months after diagnosis for 70 consecutively newly diagnosed children with T1D following implementation of an intensive management protocol was compared with 70 children consecutively diagnosed immediately pre-implementation. Intensive management involved carbohydrate counting and flexible insulin dosing from first meal with subcutaneous insulin, targeted blood glucose levels from 4-8mmol/L irrespective of time of day, avoidance of twice daily insulin regimen and promotion of continuous glucose monitoring (CGM). HbA1c, diabetes technology use and insulin regimen at 12 months post-diagnosis were compared.
Results: The post-intensive management implementation cohort had an improved mean HbA1c of 58.2±15.3mmol/mol vs 63.7±10.7mmol/mol at 12 months (p=0.014). The proportion of young people with diabetes meeting a target HbA1c of <53mmol/mol at 12 months improved from 11% to 40% (p=<0.001). There was a reduction of twice daily insulin regimen from 66% to 11% (p=<0.001), and increased CGM use from 57% to 76% (p=0.02).
Conclusion: Intensive management when implemented with consistent messaging from the multi-disciplinary team resulted in clinic-wide improvements in HbA1c and the proportion meeting HbA1c targets.
Competing Interests: None to declare.
(© PMA.)

0 (Glycated Hemoglobin)
0 (Blood Glucose)
0 (Insulin)
0 (Hypoglycemic Agents)

Date Created: 20240411 Date Completed: 20240415 Latest Revision: 20240415

20240415

10.26635/6965.6424

38603784